Pipeline Watch: Phase III Readouts For Seladelpar, Fasinumab And Carbetocin
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
The company said it was optimistic about settling opioid litigation while still anticipating going to trial on price fixing.
Further competition to Sanofi/Regeneron’s Dupixent in nasal polyps is on the horizon but the newcomers will have some catching up to do.
Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.